ArticleJournal of global health2026
B3GALT5 regulates renal A/B antigen levels: a determinant of prognosis and rejection in ABO-incompatible kidney transplantation.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ABO-incompatible (ABOi) kidney transplantation alleviates the shortage of donor kidneys. However, interventions targeting blood group antibodies alone cannot fully prevent antibody-mediated rejection. We investigated how blood group antigens affect prognosis and rejection in ABOi kidney transplantation and explored their regulatory mechanisms. Methods: We prospectively enrolled 28 consecutive ABOi kidney transplant recipient-donor pairs. We performed immunohistochemical staining for A/B antigens on intraoperative donor kidney biopsies. Graft A/B antigen expression levels were assessed in relation to post-transplant anti-A/B antibody titres, graft function, and rejection. We used transcriptome sequencing, immunohistochemistry, immunofluorescence, Western blotting, and polymerase chain reaction to preliminarily explore the regulatory mechanisms of blood group antigens. Results: We identified three expression levels of antigen A (strong, medium, and weak) and two of antigen B (strong and weak) in the grafts. Recipients of grafts with strong antigen expression showed a numerically higher proportion of immunoglobulin M (IgM) elevation. Three recipients developed blood group antibody-mediated rejection, and their graft blood group antigen levels were higher than those in other individuals (difference = 10,301.8; 95% confidence interval (CI) = 4,389.5, 14,413.2, uncorrected P = 0.0088). Recipients of grafts with weak antigen expression exhibited an improvement in estimated glomerular filtration rate within one month post-transplant (regression coefficient = 15.13; 95% CI = 0.172, 30.077, uncorrected P = 0.047). Additionally, B3GALT5, B3GNT3, and FUT9 were significantly correlated with renal blood group antigen levels, and B3GALT5 overexpression reduced blood group A antigen levels in human kidney-2 and human umbilical vein endothelial cells. Conclusions: Graft A/B antigen expression levels may be associated with anti-A/B IgM/immunoglobulin G titres, renal function, and rejection, but these findings are exploratory and require validation in larger cohorts. Furthermore, B3GALT5 shows a significant correlation with renal blood group antigen levels, and modulation of B3GALT5 can alter blood group antigen expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.